Table 3 Diagnostic and predictive WID™-qCIN assessment in distinct HPV subgroups

All, % (95% CI)

 n (controls, cases)

56, 39

116, 25

30, 73

94, 58

 Sensitivity (CIN3+)—% (95% CI)

79 (64–91)

56 (35–76)

34 (24–46)

36 (24–50)

 Specificity (≥ CIN1)—% (95% CI)

84 (72–92)

87 (80–93)

90 (73–98)

94 (87–98)

 PPV—% (95% CI)^†

58 (45–72)

54 (42–68)

48 (27–74)

61 (43–78)

 NPV—% (95% CI)^†

94 (90–97)

88 (83–92)

83 (81–86)

84 (82–87)

Age < 30 years, % (95% CI)

 n (controls, cases)

12, 14

37, 9

20, 34

40, 26

 Sensitivity (CIN3+)—% (95% CI)

79 (49–95)

33 (7–70)

18 (7–35)

12 (2–30)

 Specificity (≥ CIN1)—% (95% CI)

92 (62–100)

95 (82–99)

85 (62–97)

95 (83–99)

 PPV—% (95% CI)^†

72 (34–95)

63 (30–90)

24 (10–53)

39 (13–78)

 NPV—% (95% CI)^†

94 (87–98)

84 (78–89)

79 (75–83)

80 (77–82)

Age ≥ 30 years, % (95% CI)

 n (controls, cases)

44, 25

79, 16

10, 39

54, 32

 Sensitivity (CIN3+)—% (95% CI)

80 (59–93)

69 (41–89)

49 (32–65)

56 (38–74)

 Specificity (≥ CIN1)—% (95% CI)

82 (67–92)

84 (74–91)

100 (69–100)

93 (82–98)

 PPV—% (95% CI)^†

55 (41–70)

53 (41–68)

56 (24–79)

68 (48–85)

 NPV—% (95% CI)^†

94 (88–97)

91 (84–95)

86 (83–90)

89 (85–92)